These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 38548262)

  • 1. Tuberculosis treatment-shortening.
    Singh V
    Drug Discov Today; 2024 May; 29(5):103955. PubMed ID: 38548262
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Remembering the Host in Tuberculosis Drug Development.
    Frank DJ; Horne DJ; Dutta NK; Shaku MT; Madensein R; Hawn TR; Steyn AJC; Karakousis PC; Kana BD; Meintjes G; Laughon B; Tanvir Z
    J Infect Dis; 2019 Apr; 219(10):1518-1524. PubMed ID: 30590592
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent updates on drug resistance in Mycobacterium tuberculosis.
    Singh R; Dwivedi SP; Gaharwar US; Meena R; Rajamani P; Prasad T
    J Appl Microbiol; 2020 Jun; 128(6):1547-1567. PubMed ID: 31595643
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tuberculosis clinical trial update and the current anti-tuberculosis drug portfolio.
    Palomino JC; Martin A
    Curr Med Chem; 2013; 20(30):3785-96. PubMed ID: 23862617
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Focusing on DNA Repair and Damage Tolerance Mechanisms in Mycobacterium tuberculosis: An Emerging Therapeutic Theme.
    Mittal P; Sinha R; Kumar A; Singh P; Ngasainao MR; Singh A; Singh IK
    Curr Top Med Chem; 2020; 20(5):390-408. PubMed ID: 31924156
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Editorial: Updates from the World Health Organization (WHO) on Global Treatment Recommendations for Drug-Susceptible and Multidrug-Resistant Tuberculosis.
    Parums DV
    Med Sci Monit; 2021 Aug; 27():e934292. PubMed ID: 34366429
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent advances in the research of heterocyclic compounds as antitubercular agents.
    Yan M; Ma S
    ChemMedChem; 2012 Dec; 7(12):2063-75. PubMed ID: 23042656
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A review of recent advances in anti-tubercular drug development.
    Umumararungu T; Mukazayire MJ; Mpenda M; Mukanyangezi MF; Nkuranga JB; Mukiza J; Olawode EO
    Indian J Tuberc; 2020 Oct; 67(4):539-559. PubMed ID: 33077057
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New perspectives on the treatment of mycobacterial infections using antibiotics.
    He Y; Fan A; Han M; Zhang Y; Tong Y; Zheng G; Zhu S
    Appl Microbiol Biotechnol; 2020 May; 104(10):4197-4209. PubMed ID: 32185432
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New treatment options for multidrug-resistant tuberculosis.
    Field SK; Fisher D; Jarand JM; Cowie RL
    Ther Adv Respir Dis; 2012 Oct; 6(5):255-68. PubMed ID: 22763676
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multidrug-Resistant Tuberculosis in Child Successfully Treated with 9-Month Drug Regimen.
    Achar J; Berry C; Herboczek K; Parpieva N; Tillyashaykhov MN; Tigay ZN; Khamraev A; Velivela K; Seddon JA; du Cros P
    Emerg Infect Dis; 2015 Nov; 21(11):2105-6. PubMed ID: 26488556
    [No Abstract]   [Full Text] [Related]  

  • 12. Public-private partnership tackles TB challenges in parallel.
    Webb S
    Nat Rev Drug Discov; 2009 Aug; 8(8):599-600. PubMed ID: 19644463
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advanced cellular systems to study tuberculosis treatment.
    Bielecka MK; Elkington P
    Curr Opin Pharmacol; 2018 Oct; 42():16-21. PubMed ID: 29990957
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Revolutionizing Tuberculosis Treatment: Uncovering New Drugs and Breakthrough Inhibitors to Combat Drug-Resistant
    Verma A; Naik B; Kumar V; Mishra S; Choudhary M; Khan JM; Gupta AK; Pandey P; Rustagi S; Kakati B; Gupta S
    ACS Infect Dis; 2023 Dec; 9(12):2369-2385. PubMed ID: 37944023
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tuberculosis pharmacotherapy: strategies to optimize patient care.
    Mitnick CD; McGee B; Peloquin CA
    Expert Opin Pharmacother; 2009 Feb; 10(3):381-401. PubMed ID: 19191677
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Delamanid: From discovery to its use for pulmonary multidrug-resistant tuberculosis (MDR-TB).
    Liu Y; Matsumoto M; Ishida H; Ohguro K; Yoshitake M; Gupta R; Geiter L; Hafkin J
    Tuberculosis (Edinb); 2018 Jul; 111():20-30. PubMed ID: 30029909
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SAR analysis of new anti-TB drugs currently in pre-clinical and clinical development.
    Poce G; Cocozza M; Consalvi S; Biava M
    Eur J Med Chem; 2014 Oct; 86():335-51. PubMed ID: 25173852
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advances in Key Drug Target Identification and New Drug Development for Tuberculosis.
    Mi J; Gong W; Wu X
    Biomed Res Int; 2022; 2022():5099312. PubMed ID: 35252448
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rifampicin drug resistance and host immunity in tuberculosis: more than meets the eye.
    Bobba S; Khader SA
    Trends Immunol; 2023 Sep; 44(9):712-723. PubMed ID: 37543504
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current status and future trends in the diagnosis and treatment of drug-susceptible and multidrug-resistant tuberculosis.
    Ahmad S; Mokaddas E
    J Infect Public Health; 2014; 7(2):75-91. PubMed ID: 24216518
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.